IL161378A0 - Treatment of acute myeloid leukemia with indolinone compounds - Google Patents
Treatment of acute myeloid leukemia with indolinone compoundsInfo
- Publication number
- IL161378A0 IL161378A0 IL16137802A IL16137802A IL161378A0 IL 161378 A0 IL161378 A0 IL 161378A0 IL 16137802 A IL16137802 A IL 16137802A IL 16137802 A IL16137802 A IL 16137802A IL 161378 A0 IL161378 A0 IL 161378A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- myeloid leukemia
- acute myeloid
- indolinone compounds
- indolinone
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33062301P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034525 WO2003035009A2 (fr) | 2001-10-26 | 2002-10-28 | Traitement de la leucemie myeloide aigue a l'aide de composes d'indolinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161378A0 true IL161378A0 (en) | 2004-09-27 |
Family
ID=23290562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16137802A IL161378A0 (en) | 2001-10-26 | 2002-10-28 | Treatment of acute myeloid leukemia with indolinone compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20030130280A1 (fr) |
| EP (1) | EP1446117A4 (fr) |
| JP (1) | JP2005511540A (fr) |
| KR (1) | KR20040062591A (fr) |
| CN (1) | CN101052394A (fr) |
| AU (1) | AU2002360314B2 (fr) |
| BR (1) | BR0213960A (fr) |
| CA (1) | CA2464790A1 (fr) |
| CZ (1) | CZ2004619A3 (fr) |
| HU (1) | HUP0500422A3 (fr) |
| IL (1) | IL161378A0 (fr) |
| IS (1) | IS7222A (fr) |
| MX (1) | MXPA04003853A (fr) |
| NZ (1) | NZ532405A (fr) |
| PL (1) | PL370553A1 (fr) |
| TN (1) | TNSN04065A1 (fr) |
| TW (1) | TWI259081B (fr) |
| WO (1) | WO2003035009A2 (fr) |
| ZA (1) | ZA200403091B (fr) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2475455A1 (fr) | 2002-02-15 | 2003-08-28 | Pharmacia & Upjohn Company | Procede de preparation de derives de l'indolinone |
| US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| HN2003000272A (es) † | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
| US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| BRPI0415022A (pt) * | 2003-10-02 | 2006-11-28 | Pharmacia & Upjohn Co Llc | sais e polimorfos de um composto de indolinona substituìda com pirrol |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| CA2603445A1 (fr) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Polytherapie anticancereuse faisant intervenir du malate de sunitinib |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| MX2008001041A (es) * | 2005-09-20 | 2008-03-19 | Pfizer Prod Inc | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa. |
| JP2009508971A (ja) * | 2005-09-22 | 2009-03-05 | ザ スクリプス リサーチ インスティテュート | アルコキシインドリノン系プロテインキナーゼ阻害剤 |
| AU2006304897B2 (en) * | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
| ES2426448T3 (es) * | 2006-01-27 | 2013-10-23 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Inhibidores de proteína quinasa de pirrolo[3,2-c]piridin-4-ona 2-indolinona |
| WO2007124316A1 (fr) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Composés hétérocycliques inhibiteurs de c-fms kinase |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| NZ572072A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
| ES2383084T3 (es) | 2006-12-04 | 2012-06-18 | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. | Derivados de 3-pirrolo[b]ciclohexilen-2-dihidroindolinona y usos de los mismos |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| EP2090306A1 (fr) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2240174A1 (fr) * | 2008-02-13 | 2010-10-20 | Ratiopharm GmbH | Compositions pharmaceutiques comprenant du n-ý2-(diéthylamino)éthyl¨-5-ý(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidène)méthyl¨-2,4-diméthyl-1h-pyrrole-3-carboxamide |
| EP2113248A1 (fr) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide |
| EP2098521A1 (fr) | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide |
| WO2009157011A1 (fr) | 2008-06-23 | 2009-12-30 | Natco Pharma Limited | Procédé de préparation de sunitinib de haute pureté et de ses sels pharmaceutiquement acceptables |
| EP2138167A1 (fr) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2181991A1 (fr) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Nouveaux sels de sunitinib |
| EP2186809A1 (fr) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | Nouvelle forme cristalline du malate de sunitinib |
| EP2255792A1 (fr) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide |
| EP2264027A1 (fr) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Processus pour la préparation de N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| WO2011083124A1 (fr) | 2010-01-05 | 2011-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonistes du récepteur flt3 destinés au traitement ou à la prévention de troubles douloureux |
| EA022188B1 (ru) | 2010-01-12 | 2015-11-30 | Аб Сьянс | Оксазольные ингибиторы киназы, содержащие их композиции и их применение |
| WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
| EP2654799B1 (fr) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Conjugués polymère-sunitinib |
| EP2654797B1 (fr) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Conjugués polymère-dés-éthyl sunitinib |
| ES2608628T3 (es) | 2012-08-07 | 2017-04-12 | Janssen Pharmaceutica Nv | Procedimiento para la preparacion de derivados de ester heterociclicos |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2014100716A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| CN103274986A (zh) * | 2013-06-20 | 2013-09-04 | 湖南欧亚生物有限公司 | 一种舒尼替尼中间体的合成和精制方法 |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| WO2016016370A1 (fr) | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonistes des récepteurs flt3 |
| WO2016022605A1 (fr) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| EP3254698A1 (fr) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique |
| CN108778276A (zh) | 2016-11-02 | 2018-11-09 | 安罗格制药有限责任公司 | 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
| WO2018211018A1 (fr) | 2017-05-17 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibiteurs de flt3 pour améliorer des traitements de la douleur par des opioïdes |
| WO2019057649A1 (fr) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de la leucémie myéloïde aiguë |
| US11713310B2 (en) | 2020-07-20 | 2023-08-01 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
| WO2022090547A1 (fr) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production de caroténoïdes par fermentation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5031249A1 (es) * | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
| ES2267605T3 (es) * | 1999-12-22 | 2007-03-16 | Sugen, Inc. | Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa. |
| ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| AR035721A1 (es) * | 2000-12-20 | 2004-07-07 | Sugen Inc | Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| BR0213185A (pt) * | 2001-10-10 | 2004-09-14 | Sugen Inc | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase |
-
2002
- 2002-10-25 TW TW091125049A patent/TWI259081B/zh not_active IP Right Cessation
- 2002-10-28 CA CA002464790A patent/CA2464790A1/fr not_active Abandoned
- 2002-10-28 CZ CZ2004619A patent/CZ2004619A3/cs unknown
- 2002-10-28 IL IL16137802A patent/IL161378A0/xx unknown
- 2002-10-28 PL PL02370553A patent/PL370553A1/xx not_active Application Discontinuation
- 2002-10-28 BR BR0213960-0A patent/BR0213960A/pt not_active IP Right Cessation
- 2002-10-28 EP EP02795563A patent/EP1446117A4/fr not_active Withdrawn
- 2002-10-28 AU AU2002360314A patent/AU2002360314B2/en not_active Ceased
- 2002-10-28 NZ NZ532405A patent/NZ532405A/en unknown
- 2002-10-28 WO PCT/US2002/034525 patent/WO2003035009A2/fr not_active Ceased
- 2002-10-28 CN CNA028229592A patent/CN101052394A/zh active Pending
- 2002-10-28 HU HU0500422A patent/HUP0500422A3/hu unknown
- 2002-10-28 MX MXPA04003853A patent/MXPA04003853A/es not_active Application Discontinuation
- 2002-10-28 JP JP2003537578A patent/JP2005511540A/ja not_active Withdrawn
- 2002-10-28 KR KR10-2004-7006222A patent/KR20040062591A/ko not_active Ceased
- 2002-10-28 US US10/281,266 patent/US20030130280A1/en not_active Abandoned
-
2004
- 2004-04-15 IS IS7222A patent/IS7222A/is unknown
- 2004-04-16 TN TNP2004000065A patent/TNSN04065A1/en unknown
- 2004-04-22 ZA ZA200403091A patent/ZA200403091B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030130280A1 (en) | 2003-07-10 |
| JP2005511540A (ja) | 2005-04-28 |
| TWI259081B (en) | 2006-08-01 |
| KR20040062591A (ko) | 2004-07-07 |
| WO2003035009A3 (fr) | 2004-03-18 |
| NZ532405A (en) | 2005-12-23 |
| HUP0500422A3 (en) | 2009-09-28 |
| CZ2004619A3 (cs) | 2005-03-16 |
| HUP0500422A2 (hu) | 2005-11-28 |
| EP1446117A4 (fr) | 2008-01-23 |
| MXPA04003853A (es) | 2005-02-17 |
| AU2002360314B2 (en) | 2007-09-20 |
| PL370553A1 (en) | 2005-05-30 |
| IS7222A (is) | 2004-04-15 |
| WO2003035009A2 (fr) | 2003-05-01 |
| BR0213960A (pt) | 2004-08-31 |
| CA2464790A1 (fr) | 2003-05-01 |
| EP1446117A2 (fr) | 2004-08-18 |
| TNSN04065A1 (en) | 2006-06-01 |
| CN101052394A (zh) | 2007-10-10 |
| ZA200403091B (en) | 2005-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161378A0 (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
| ZA200305691B (en) | The use of substituted azetidione compounds for the treatment of sitosterolemia | |
| SI1578446T1 (sl) | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega | |
| IL157425A0 (en) | Treatment of solid tumours with paramycin derivatives | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| IL161511A0 (en) | Therapeutic isoquinoline compounds | |
| IL161597A0 (en) | Therapeutic quinoline compounds with 5-ht-antagonistic properties | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| IL161509A0 (en) | Therapeutic quinolone compounds with 5-ht-antogonistic properties | |
| PL378762A1 (pl) | Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi | |
| PL377464A1 (pl) | Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN | |
| HU0103986D0 (en) | New compounds with therapeutic effect | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| EP1461030A4 (fr) | Composes d'aminoalkyl-benzofuran-5-ol pour le traitement du glaucome | |
| HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| IL161748A0 (en) | New use for the treatment of gastroesophageal reflux | |
| AU2002364711A8 (en) | Substituted 5-hydroxy-indole compounds for the treatment of glaucoma | |
| AU2002304883A1 (en) | Device for the treatment of tumours | |
| GB0103031D0 (en) | Novel treatment | |
| AU2002341485A1 (en) | Treatment of polyaluminium compounds | |
| SI1485352T1 (en) | Azaspiro compounds for the treatment of pain | |
| SI1485057T1 (sl) | Derivati azaspiro spojin za zdravljenje bolecine | |
| GB0120654D0 (en) | Treatment of anemia | |
| GB0120406D0 (en) | Treatment of anemia | |
| GB0101636D0 (en) | Therapeutic compounds |